Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
Absent, Amgen, BI, BMI, CagriSema, ceiling, confidence, depositary, deterioration, disagreement, efocipegtrutide, indeterminate, Indiana, Iowa, Israel, liraglutide, Montana, Mounjaro, orforglipron, overweight, pemvidutide, percent, rencofilstat, retatrutide, Saxenda, seasoned, sovereign, survodutide, Tennessee, threatened, unemployment, unsold, VENTURE, weekly, Wegovy, Zealand
Removed:
Bristol, disadvantage, incurring, landscape, legally, managing, mandated, quickly, respond, Squibb
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view